tirzepatide surpass 2 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Efficacy of tirzepatide 5, 10

Pediatric (12 years and older) Wegovy 1.7 or 2.4 mg once weekly Cardiovascular Risk Reduction Wegovy 1.7 or 2.4 mg once weekly MASH Wegovy 2.4 mg once weekly

Laccumulation de lactates dans le muscle est un facteur limitant pour la performance, ainsi que les courbatures et les douleurs musculaires ressenties

As summarized by the American Journal of Managed Care: "Physicians have pointed out that no other chronic condition in Medicare is treated this way with an effective medication offered temporarily and then potentially withdrawn." For obesity, which is classified as a chronic condition by the American Medical Association and most major medical societies, offering 18 months of effective treatment with no guaranteed continuation is clinically unusual

Visible changes in how clothes fit and how you feel often precede obvious scale movement, so paying attention to non-scale victories like increased energy and reduced food cravings is valuable early feedback

Meal Planning for Weight Loss: Prepare meals ahead of time to avoid impulsive eating

(+), trend improvement in predefined outcome